Therapies targeting late events in Alzheimer's disease (AD), including aggregation of
amyloid beta (Aβ) and hyperphosphorylated tau, have largely failed, probably because they …

Reductions of baseline cerebral blood flow (CBF) of∼ 10–20% are a common symptom of
Alzheimer's disease (AD) that appear early in disease progression and correlate with the …

Structural and functional integrity of the cerebral vasculature ensures proper brain
development and function, as well as healthy aging. The inability of the brain to store energy …

Components of the neurovascular unit (NVU) establish dynamic crosstalk that regulates
cerebral blood flow and maintain brain homeostasis. Here, we describe accumulating …

Amyloidogenicity and vascular dysfunction are the key players in the pathogenesis of
Alzheimer's disease (AD), involving dysregulated cellular interactions. An intricate balance …

Neuroimaging refers to the techniques that provide efficient information about the neural
structure of the human brain, which is utilized for diagnosis, treatment, and scientific …

Amyloid-beta (Aβ) plays an important role in the pathogenesis of Alzheimer's disease.
Aberrant Aβ accumulation induces neuroinflammation, cerebrovascular alterations, and …

Abstract Changes in amyloid-beta-oligomer (AβΟ) peptides levels are considered one of the
major neuropathologic biomarkers for Alzheimer's Disease (AD). AβΟ levels can be …

Magnetic resonance imaging (MRI) and positron emission tomography (PET) have made
great strides in the diagnosis and our understanding of Alzheimer's Disease (AD). Despite …

Life expectancy decreases with aging, with cardiovascular, mental health, and
neurodegenerative disorders strongly contributing to the total disability-adjusted life years …